01—Abstract
Summary
Summary of the 8-K filed March 26, 2024. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation (EW) announced significant changes to its Board of Directors, effective in conjunction with the upcoming 2024 Annual Meeting of Stockholders on May 7, 2024.
Most notably, Michael A. Mussallem, the current Non-Executive Chairman, has decided to retire from his position and will not seek re-election to the Board. This marks the end of a long tenure for Mr. Mussallem, who has been instrumental in the company's leadership.
02—Key points
Key Highlights
- Michael A. Mussallem to retire as Non-Executive Chairman and director, effective May 7, 2024.
- Mr. Mussallem will not stand for re-election at the 2024 Annual Meeting of Stockholders.
- Nicholas J. Valeriani, an independent director, is expected to be appointed as the new Chairman of the Board.
- Martha H. Marsh will also not be nominated for re-election to the Board due to reaching the company's retirement age.
- These leadership changes are effective in conjunction with the annual meeting of stockholders on May 7, 2024.
03—Questions
Frequently Asked Questions
Who is replacing Michael A. Mussallem as Chairman of the Board?
Nicholas J. Valeriani, who is currently an independent director on the Board, is expected to be appointed as the new Chairman of the Board.
When will these changes to the Board of Directors take effect?
The changes will be effective in conjunction with Edwards Lifesciences' 2024 Annual Meeting of Stockholders, which is scheduled for May 7, 2024.
Are there any other directors not standing for re-election?
Yes, Martha H. Marsh will also not be nominated for re-election to the Board as she has reached the company's established retirement age.
What is the significance of Michael A. Mussallem's retirement?
Michael A. Mussallem's retirement as Non-Executive Chairman signifies a transition in the company's board leadership. Investors will be looking for continuity and a clear strategic vision from the incoming Chairman, Nicholas J. Valeriani.
04—Continue